Tomas Leanderson

Overview

Best Publications

• Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides

  Per Björk;Anders Björk;Thomas Vogl;Martin Stenström

  472
  Citations

• Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock.

  Marina Karaghiosoff;Ralf Steinborn;Pavel Kovarik;Gernot Kriegshäuser

  446
  Citations

• Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria

  Giuseppe Mancuso;Angelina Midiri;Carmelo Biondo;Concetta Beninati

  315
  Citations

• IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis.

  Ingrid Teige;Alexandra Treschow;Anna Teige;Ragnar Mattsson

  288
  Citations

• Interferon-β is required for interferon-α production in mouse fibroblasts

  Lena Erlandsson;Ralf Blumenthal;Maija-Leena Eloranta;Holger Engel

  254
  Citations

• Extracellular MRP8/14 is a regulator of β2 integrin-dependent neutrophil slow rolling and adhesion

  Monika Pruenster;Angela R. M. Kurz;Kyoung-Jin Chung;Xiao Cao-Ehlker

  202
  Citations

• Autoinhibitory regulation of S100A8/S100A9 alarmin activity locally restricts sterile inflammation

  Thomas Vogl;Athanasios Stratis;Viktor Wixler;Tom Völler

  195
  Citations

• Antioxidant metabolism induced by quinic acid. Increased urinary excretion of tryptophan and nicotinamide.

  Ronald W. Pero;Harald Lund;Tomas Leanderson

  181
  Citations

• S100A9 Interaction with TLR4 Promotes Tumor Growth

  Eva Källberg;Thomas Vogl;David Liberg;Anders Olsson

  173
  Citations

• Induction of nuclear factor-κB responses by the S100A9 protein is Toll-like receptor-4-dependent.

  Matteo Riva;Eva Källberg;Per Björk;Dora Hancz

  161
  Citations

• Lack of J Chain Inhibits the Transport of Gut IgA and Abrogates the Development of Intestinal Antitoxic Protection

  Nils Lycke;Lena Erlandsson;Lena Ekman;Karin Schön

  161
  Citations

• In vivo anergized CD4+ T cells express perturbed AP-1 and NF-kappa B transcription factors.

  Anette Sundstedt;Mikael Sigvardsson;Tomas Leanderson;Gunnar Hedlund

  156
  Citations

• Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.

  Anders A. Bengtsson;Gunnar Sturfelt;Christian Lood;Lars Rönnblom

  155
  Citations

• Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

  Anders Olsson;Anders Björk;Johan Vallon-Christersson;John T Isaacs

  125
  Citations

• Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus

  Helena Tydén;Christian Lood;Birgitta Gullstrand;Andreas Jönsen

  113
  Citations

• Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment

  John T. Isaacs;Lizamma Antony;Susan L. Dalrymple;W. Nathaniel Brennen

  112
  Citations

• Expansion, selection and mutation of antigen-specific B cells in germinal centers.

  Tomas Leanderson;Eva Kallberg;David Gray

  111
  Citations

• Identification of ABR‐215050 as lead second generation quinoline‐3‐carboxamide anti‐angiogenic agent for the treatment of prostate cancer

  John T. Isaacs;Roberto Pili;David Z. Qian;Susan L. Dalrymple

  102
  Citations

• Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models

  Li Shen;Anette Sundstedt;Michael Ciesielski;Kiersten Marie Miles

  100
  Citations

• Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis.

  R F Schelbergen;E J Geven;M H J van den Bosch;H Eriksson

  98
  Citations